CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤新型疗法的心脏毒性：CAR-T 细胞疗法与双特异性 T 细胞衔接器疗法
英文原题：Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy.
查看英文原题
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
恶性血液学领域正随着新型免疫治疗方法而发生变革。遗憾的是，生活质量、治疗效果和预期寿命受到治疗心脏毒性副作用的不利影响。迄今为止，与这些治疗相关的心脏毒性的确切机制和发生率尚不清楚。这些事件被认为由细胞因子释放综合征触发或与之同时发生。此外，尚无正式指南提供评估、治疗和监测。我们旨在综合现有文献，并更新用于恶性血液疾病的新型疗法的心脏毒性效应，重点关注CAR-T 细胞疗法和双特异性 T 细胞衔接器疗法，同时提出一种算法，以指导治疗前评估、治疗期间监测和治疗后监测。
展开英文摘要原文
The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome.
Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance.
We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
论文信息
- 作者
- Marar RI、Abbasi MA、Prathivadhi-Bhayankaram S、Daryanani A、Villarraga H、Anavekar N、Bhatt VR、Paludo J
- 第一作者单位
- Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.United States
- 通讯作者单位
- Division of Hematology-Oncology, Mayo Clinic, Rochester, MN.United States
- 期刊
- JCO oncology practice2023 Jun
- 原文标识
- PubMed 36930845 · DOI 10.1200/OP.22.00713